Introduction
IL-3 acts to promote the survival and to stimulate the proliferation of haemopoietic cells by interacting with a heterodimeric receptor which is a member of the haemopoietin receptor superfamily; the b chain of this receptor is shared with the receptors for GM-CSF and IL-5 (Hara and Miyajima, 1996) . Membrane proximal domains of the cytoplasmic tail of the common b chain associate with the tyrosine kinase Jak2 and src family kinases (Rao and Mufson, 1995; Quelle et al., 1994) . Upon IL-3 stimulation, the common b chain becomes tyrosine phosphorylated leading to association with, and phosphorylation of, the adapter protein Shc (Welham et al., 1994; Pratt et al., 1996) . Shc binding leads ultimately to activation of Ras which results in the stimulation of mitogen-activated protein (MAP) kinases, extracellular signal-regulated kinase (ERK2) and c-jun N-terminal kinase/stress activated protein kinase (JNK/SAPK) (Sato et al., 1993; Welham et al., 1992; Terada et al., 1997) . Phosphatidylinositol-3 kinase (PI3K) also becomes activated upon IL-3 stimulation, following association of its p85 regulatory subunit with src family kinases (Jucker and Feldman, 1995) . Jak2 is essential for IL-3 signalling and conditional activation of Jak2 can replace IL-3 in supporting survival and proliferation (Mizuguchi and Hatekeyama, 1998) . Subsequent ERK2 (Perkins et al., 1996) and JNK/SAPK stimulation by IL-3 are also required for cell survival and proliferation.
IL-3 regulates cell survival in part by regulating activity of the apoptosis inhibitor Bcl-X. The level of Bcl-X gene expression is maintained by IL-3 (Leverrier et al., 1997) . This is through a Jak2-dependent pathway (Packham et al., 1998) , although the role of the transcription factor STAT5 in this regulation remains controversial (Dumon et al., 1999; Nosaka et al., 1999) . In retroviral mutagenesis experiments, IL-3-independent mutants are isolated in which Bcl-X expression is maintained in the absence of IL-3, by an insertion into the Bcl-X gene . This demonstrates that up-regulation of Bcl-X gene expression is a critical function of IL-3. IL-3 also maintains hyperphosphorylation of the pro-apoptotic BAD, preventing its binding to Bcl-X (Zha et al., 1996) . One proposed mechanism by which Bcl-X inhibits apoptosis is by sequestering the apoptosis eector Bax, and it has been shown that BAD binding to Bcl-X displaces Bax (Yang et al., 1995) . However, mutants of Bcl-X which fail to bind Bax can still inhibit apoptosis (Cheng et al., 1996) .
Bax moves from the cell cytosol to mitochondria during apoptosis (Wolter et al., 1997) . In IL-3-dependent cells Bax becomes dimerized and translocates 12 h after factor removal, approximately the time when cells become commited to die and caspase-9 cleavage is observed . An Nterminal domain of Bax becomes exposed to antibody recognition upon membrane association (Hsu and Youle, 1998) , and a mutant Bax lacking the N-terminal domain constitutively associates with membranes (Goping et al., 1998) . Mutations in the hydrophobic C-terminus of Bax can also cause constitutive membrane association (Nechustan et al., 1999) . The proposed mechanism is that the conformation of the N-terminus can regulate C-terminus exposure and membrane attachment (Nechustan et al., 1999) . The structure of Bax shows that dimerization is likely to cause membrane association (Suzuki et al., 2000) . Enforced dimerization of Bax which leads to membrane association, or mutations in Bax which cause constitutive membrane association, all induce apoptosis Goping et al., 1998; Nechustan et al., 1999) . Therefore, membrane association is believed to be critical for Bax toxicity. Indeed, some 20% of human haematopoietic tumour cell lines possess Bax mutations, including some with altered dimerization (Meijerink et al., 1998) . Loss of Bax alleles has also been documented during tumour development in mouse models (Ionov et al., 2000; Shibata et al., 1999) . One of the mechanisms by which membrane association of Bax causes apoptosis is to release cytochrome c from mitochondria (Jurgenmeister et al., 1998; Finucane et al., 1999) , which is critical for eector caspase activation (Li et al., 1997) . Bax does not undergo its N-terminal conformational change or become membrane associated in IL-3-dependent cells over-expressing Bcl-2 (Murphy et al., 2000; .
In this study, we describe the role of Bax membrane association and its relationship to the decrease in Bcl-X expression, during apoptosis induced by IL-3 removal from mouse bone marrow-derived cells. We also show that Bax is not required for killing o IL-3-dependent cells by DNA damaging agents or inhibitors of nucleotide metabolism.
Results

Bax is required for efficient apoptosis on IL-3 removal
As Bax becomes membrane associated on IL-3 removal from cytokine-dependent cells, we examined whether Bax was critical for death of these cells in the absence of IL-3. Figure 1a shows that IL-3-dependent cells from Bax-null mice did not activate caspases upon IL-3 removal in contrast to cells from wild-type littermate controls. A previous study described that such Bax-null cultures also remained viable after 24 h IL-3 deprivation, in contrast to wild-type controls (Maurer et al., 2000) . A dierence between the cultures was also observed when their survival and proliferation in limiting concentrations of IL-3 was examined. Figure  1b shows that the Bax-null cells were able to form clonal colonies in up to 10-fold lower levels of IL-3. However, they did not survive in the long term (data not shown) or proliferate to form colonies (Figure 1b) , in the complete absence of IL-3. These data lead us to conclude that cell death after IL-3 removal proceeds less eciently in the absence of Bax. However, inhibition of Bax function is not the only role of IL-3 as Bax-null cells do not survive in its absence.
A Bcl-X decrease is not sufficient to allow Bax membrane association
To examine the level of Bcl-X in cells which have entered apoptosis, we deprived the cytokine-dependent cell line BAF-3 of IL-3 for 17 h then isolated a caspase-inactive and a caspase-active population using Figure 1 Bax is necessary for cell death after IL-3 decrease. (a) Wild-type (wt) or Bax-null (k/o) IL-3 dependent bone marrow cells were incubated for 17 h with or without IL-3. They were then stained with the caspase substrate PhiPhiLux and caspaseinactive and caspase-active populations were analysed by FACScan as described in Materials and methods. (b) The plating eciency of cultures from Bax-null mice or normal littermate controls in various concentrations of IL-3 was measured, as described in Materials and methods. This was then expressed as a fraction of the plating eciency in 10% WEHI-CM. Values shown are the mean+standard error of triplicate determinations performed with independent cultures a cell permeable caspase substrate and a cell sorter. The caspase-inactive and caspase-active populations are observed because cells enter apoptosis asynchronously. The event which triggers entry into apoptosis remains unclear, we have previously shown that it is unrelated to the position of cells in the cell cycle (Silva et al., 1997) . Figure 2a shows that the sorted caspaseinactive population retained full plating eciency, whereas the caspase-active population were committed to die. However, the level of Bcl-X expressed in the two cell populations was identical (Figure 2a ). This result was also obtained in a second, separate experiment (data not shown). Therefore a detectable decrease in Bcl-X expression does not trigger commitment to cell death after IL-3 removal.
We noted that a lower molecular weight form of Bax, approximately 18 kDa compared to the 21 kDa full-length Bax, appeared in the caspase-active cell population ( Figure 2a) . A similar form of Bax was observed by Wood et al. (1998) during drug-induced apoptosis of HL60 cells. They reported that Bax was cleaved during apoptosis, to remove the N-terminal 33 amino acids. Figure 2b shows that the 18 kDa form of Bax observed on IL-3 removal could be detected only by antisera raised against an internal Bax peptide (A and B), and not by those raised against an N-terminal peptide (C and D) . This demonstrates that cleavage of an N-terminal portion of Bax also occurs during apoptosis following IL-3 removal. The role of this cleavage in the mechanism of action of Bax remains unclear. An Asp 33 -Ala 33 Bax mutant, which was reported to not be cleaved (Wood et al., 1998) , shows equivalent toxicity to wild-type Bas when overexpressed in 293T or 3T3 cells (data not shown).
To further investigate the eect of decreasing Bcl-X expression on entry into apoptosis, we used inhibitors of IL-3 signalling to block IL-3 induction of Bcl-X gene expression. We previously reported that reduced Bcl-X induction by IL-3 was observed in the D16 BAF-3 sub-clone, which expresses dominant-negative MEK1 (Leverrier et al., 1997) and the PI3-kinase inhibitor Ly294002 has been reported to inhibit Bcl-X induction by IL-2 in resting T lymphocytes (GonzalezGarcia et al., 1997) . Figure 3a shows that a combination of Ly294002 and the MEK1/2 inhibitor PD98059 completely blocked induction of Bcl-X mRNA expression by IL-3. The Bcl-X protein was relatively stable; however cells maintained in the presence of IL-3 plus Ly294002 and PD98059 for 48 h expressed a greatly reduced level of Bcl-X ( Figure  3b ), which was lower than that observed in cells entering apoptosis in the absence of IL-3 (Figure 2a ). These cells with a greatly reduced level of Bcl-X, remained viable (Figure 3c ), retained a high plating eciency ( Figure 3d ) and maintained Bax distributed between soluble and membrane-associated forms (Figure 3d ). This demonstrates that a further signal from the IL-3 receptor maintains Bax in a soluble form, even when Bcl-X expression is greatly reduced.
A Bcl-X decrease is necessary for Bax membrane association after IL-3 removal Gross et al. (1998) reported that Bax does not become membrane associated in IL-3-dependent cells overexpressing Bcl-2. We wished to extend this observation to cells which maintain a normal level of Bcl-X when IL-3 is removed. We therefore used the cell clone vi34 , which is a BAF-3 derivative containing a retroviral insertion in the Bcl-X locus. Figure 4a shows that these cells expressed approximately twofold more Bcl-X than BAF-3 in the presence of IL-3, and maintained a normal level of Bcl-X expression after IL-3 removal. The vi34 cells also remained fully viable when IL-3 was removed and did not show increased membrane-association of Bax (Figure 4b ). These results of Figure 4 demonstrate that a Bcl-X decrease is necessary for Bax membrane association after IL-3 is removed.
Several cytotoxic stimuli do not require Bax to kill cells
We have previously examined the ability of IL-3 to protect BAF-3 cells from apoptosis induced by cytotoxic drugs. We reported that IL-3 could prevent
Figure 2 (a) Bcl-X level does not control caspase activation after IL-3 removal. BAF-3 cells were incubated for 17 h without IL-3. They were then stained with the caspase substrate PhiPhiLux and caspase-inactive (A) and caspase-active (B) populations were separated by FACS as described in Materials and methods. The plating eciencies of populations A and B were determined as described in Materials and methods. 10 6 cells from populations A or B and 10 6 cells incubated in the absence or presence of IL-3 for 17 h were used to analyse Bcl-X and Bax expression, as described in Materials and methods. (b) Bax cleavage removes an Nterminal epitope. BAF-3 cells were incubated in the absence or presence of IL-3 for 17 h. Total cellular protein samples were then analysed by immunoblotting with the anti-Bax antiserum used elsewhere (serum A), a second anti-Bax antiserum raised against an internal peptide epitope (serum B) and two anti-Bax antisera raised against an N-terminal peptided (sera C and D), as described in Materials and methods
Role of Bax in apoptosis of IL-3-dependent cells
W Low et al apoptosis induced by a number of DNA-damaging agents (Collins et al., 1992) . However, IL-3 was unable to inhibit apoptosis induced by inhibitors of deoxynucleotide metabolism (Oliver et al., 1997) . We therefore reasoned that hydroxyurea which inhibits ribonucleotide reductase, a key enzyme in dNTP synthesis, might induce apoptosis in the absence of a decrease in Bcl-X. As might be predicted, hydroxyurea was also able to induce cell death in the vi34 cells in the presence of IL-3 (Figure 5a ). This cell death, in response to hydroxyurea, occurred in the absence of any detectable Bcl-X decrease in the bulk cell population (Figure 5b ). We also demonstrated that the caspase-active cells following hydroxyurea treatment, which were committed to apoptosis, expressed the same level of Bcl-X as the caspase-inactive cells (Figure 5c ). These data demonstrate that hydroxyurea induced some Bax membrane association and cleavage in both BAF-3 cells and vi34 cells in the presence of IL-3, though much less than that observed after IL-3 removal (Figure 3) . We therefore examined whether Bax was required for cell death in response to hydroxyurea. Figure 6a shows that caspase activation was induced by hydroxyurea in IL-3-dependent cells from Bax-null mice, to a similar level to that induced in wild-type controls. Bax-null cells also showed normal loss of cloneginicity in response to hydroxyurea (Figure 6b ). Indeed Bax was not required for cell killing by a number of agents which inhibit nucleotide metabolism (hydroxyurea, methotrexate or FUdR) or which damage DNA (X-irradiation or cisplatin) (Table 1 ). This is in contrast to our ®ndings with p53-null IL-3 dependent cells which were highly resistant to the inhibitors of nucleotide metabolism, though not to DNA-damaging agents (Palacios et al., 2000) . Therefore, although Bax can be up-regulated by p53 (Selvakumaran et al., 1995) , Bax up-regulation cannot be required for p53-dependent cell killing by hydroxy-urea, methotrexate or FUdR.
Discussion
The Bax knockout mouse shows lymphoid and ovarian hyperplasia (Knudson et al., 1995) , suggesting that Bax (7), for 2 h with IL-3. Where indicated, 30 mM LY294002 (LY) and 100 mM PD98059 (PD) were added at the time of re-induction. Total RNA was extracted and a Northern blot was hybridized with Bcl-X and GAPDH probes as described in Materials and methods. (b) BAF-3 cells were incubated for the time shown in the absence or presence of IL-3 and 30 mM LY294002 (LY) and 100 mM PD98059 (PD) as indicated. Total cellular protein samples were analysed by immunoblotting as described in Materials and methods. (c) BAF-3 cells were plated in the absence or presence of IL-3, 30 mM LY294002 (LY) and 100 mM PD98059 (PD) as indicated. At the time shown, cell viability was determined as described in Materials and methods. The results represent the percentage of viable cells and are the mean of duplicate determinations. (d) BAF-3 cells were incubated for 48 h in the absence or presence of IL-3 and 30 mM LY294002 (LY) and 100 mM PD98059 (PD) as indicated. Plating eciency was then determined and extracts of total (T), soluble (S) and membrane (M) proteins were analysed by immunoblotting plays a role in apoptosis of cells within these tissues during development. Cultured neurons from Bax-null mice also show decreased apoptosis upon trophic factor withdrawal (Deckwerth et al., 1996) in a similar manner to the IL-3 dependent cultures described here. Bax has also been reported to be required for radiation-induced death of neurons (Johnson et al., 1998; Chong et al., 2000) . However, colonic epithelial cells of Bax-null mice show normal apoptosis in response to radiation or FUdR (Pritchard et al., 1999) , as do the IL-3 dependent cultures. Knockout of Bax in human colorectal cancer cells also resulted in a modest eect on their response to FUdR, but complete prevention of cell death in response to nonsteroidal anti-in¯ammatory drugs (Zhang et al., 2000) . Thus, there is no consistent picture of the role of Bax in apoptosis in response to survival factor removal or cytotoxic drugs; its eects appear to be cell type speci®c.
This report describes two mechanisms by which IL-3 prevents apoptosis. Firstly, IL-3 regulates expression of the anti-apoptotic protein Bcl-X and secondly IL-3 directly inhibits Bax membrane association in cells with down-regulated Bcl-X expression. This is in agreement with our previous study which showed that IL-3 could rescue cells which had down-regulated Bcl-X in the absence of de novo Bcl-X synthesis (Leverrier et al., 1997) . The pathway by which IL-3 directly prevents Bax membrane association is independent of MEK1/2 and PI3-kinase signalling. A Bcl-X decrease is also necessary to allow Bax membrane association in cells deprived of IL-3, because maintaining Bcl-X expression in the absence of IL-3 also inhibits Bax translocation. This is in agreement with the observation that Bax does not become membrane associated in cells deprived of IL-3 which over-express Bcl-2 . However, it is dierent from the response of neurons deprived of NGF, where Bcl-2 does not prevent Bax membrane-association, but does prevent the release of cytochrome c from mitochondria (Putcha et al., 1999) .
The mechanism by which Bax membrane association is controlled after IL-3 removal remains unclear. An increase in cytoplasmic pH after IL-3 or IL7 withdrawal has been detected, which induces an unfolding of Bax which would favour membrane association (Khaled et al., 1999) . We have described a decrease in cytoplasmic pH following IL-3 withdrawal (Furlong et al., 1997) , which might lead to Bax dimerization . In cells over-expressing Bcl-2 this pH decrease was delayed by 10 h, but eventually the cells moved to a viable population with low pH (Furlong et al., 1997) . This argued against intracellular acidi®cation as the sole controlling signal. Further BH3 domain only proteins, in addition to Bad, are also candidates for the role of Bax translocation regulator (reviewed in Huang and Strasser, 2000) . Indeed Bid, which is cleaved and activated by caspase-8 after Fas triggering (Li et al., 1998) , induces a conformational change in Bax (Perez and White, 2000) and stimulates Bax insertion into isolated mitochondria (Eskes et al., 2000) . However we have ruled out a role for Fas signalling in apoptosis following IL-3 withdrawal, as IL-3-dependent bone marrow cultures from lpr/lpr mice died with normal kinetics when IL-3 was removed (data not shown). The recent study (Sanz et al., 2000) that expression of the BH3 domain protein Hrk is upregulated by IL-3 removal from factor-dependent cell lines remains intriguing. However, new protein synthesis is not required for Bax translocation in BAF3 cells (data not shown) or their death following IL-3 removal (Collins et al., 1992) .
Materials and methods
Cell culture
BAF-3 cells (Palacios and Steinmetz, 1985) and vi34 cells were maintained in Dulbecco's modi®ed Eagle's Medium (DMEM) containing 10% foetal calf serum (FCS), 50 IU/ml Penicillin/Streptomycin (GIBCO/ BRL) and 1% WEHI-3B conditioned medium as a source of IL-3. LY 294002 (Calbiochem) and PD98059 (New England Bio Labs) were used at ®nal concentration of 30 mM, 100 mM respectively. Cisplatin was obtained from David Bull Labs and hydroxyurea, methotrexate and 5-¯uorouracil from Sigma. Cell viability was determined by counting cells able to exclude trypan blue on a haemocytometer. Bone marrow was aspirated from the femurs of Bax-null mice or normal littermate controls (C57BL/6-Bax tm1Sjk , (Knudson et al., 1995) heterozygotes obtained from Jackson Laboratories), then Plating eciency was then determined and extracts of total (T), soluble (S) and membrane (M) proteins were analysed by immunoblotting, as described in Materials and methods cultured for 14 ± 21 days in DMEM/10% FBS with 2% WEHI-3B conditioned medium as a source of IL-3. At this point the cultures represent 490% IL-3-dependent mast cells, as previously described (Silva et al., 1997) . Plating eciency was measured after serial twofold dilution of cells plated in a 96 well plate. Between 10 and 15 days after plating, positive wells were evaluated by microscopy. Plating eciency was calculated from the dilution where less than 30% of wells were positive, where the positives can be assumed to have derived from single cell clones.
RNA extraction and Northern blot analysis
Total cellular RNA was isolated using the RNAzol TM B (Biogenesis) method, in accordance with the manufacturer's instructions. For RNA blot analysis, 10 mg of total RNA was loaded in each slot of a 1% agarose-formaldehyde gel and transferred to a nylon Hybond TM -N+ membrane (Amersham). Pre-hybridization, hybridization and washes of the membrane were performed using the Hybond TM -N+ recommended protocol. The murine Bcl-X L (0.8 Kbp) and GAPDH (1 Kbp) probes were labelled with [a 32 P]dCTP (Amersham) using a random prime labelling system (Promega).
Cell staining with PhiPhiLux and sorting
After incubation as shown, cells were pelleted and washed with 1 ml of PBS. 10 7 cells were resuspended in 50 ml of PhiPhiLux reagent (Alexis Biochemicals) to which 10% FCS and 5% WEHI had been added. Cells were incubated for 1 h at 378C, washed in 1 ml PBS, then resuspended in 1 ml PBS. 10 6 PhiPhiLux positive or negative cells were sorted for immunoblotting, using a Coulter Epics Elite sorter with a 75 mm¯ow cell and Expo300 software (Applied Cytometry 
Immunoblotting analysis
5610
6 cells were pelleted, washed with 1 ml of PBS, then resuspended in 50 ml PBS plus 10 ml 66reducing Laemmli sample buer. For soluble and membrane samples, 2610 7 cells were pelleted, washed with 1 ml PBS and resuspended in 200 ml of ice-cold lysis buer (10 mM Tris pH 7.9, 3 mM MgCl 2 , 10 mM NaCl and protease inhibitors). After 15 min incubation on ice, 50 ml was removed as a`total' sample, then lysates were centrifuged at 10 000 g for 10 min at 48C. The supernatant was then removed (`soluble' sample) and the pellet was resuspended in 150 ml of lysis buer (`membrane' sample). For all gels an equivalent of 10 6 cells per lane was loaded. Samples were heated at 958C, then proteins were separated by 15% SDS-polyacrylamide gel. After electrophoresis the proteins were transferred to a nitrocellulose membrane which was blocked overnight with PBS plus 0.05% Tween-20 and 5% milk. The membranes were incubated for 1 h with anti-Bax (serum A unless speci®ed, generous gift of Dr J Ham (Vekrellis et al., 1997) 3 0 4 0 *The plating eciency of IL-3-dependent bone marrow cultures from Bax-null mice or normal littermate controls was measured after various levels of X-irradiation (Pantac X-ray machine with an output of 240 KeV at a dose rate of 3 ± 4 Gy/min); cisplatin (24 h exposure); hydroxyurea, methotrexate or FUdR (continuous exposure), as described in Figure 1 . In each case the dose required to induce a 50% loss of clonigenicity was determined from graphs similar to those of Figure 6 Figure 6 Bax is not necessary for cell death in response to hydroxyurea. (a) Wild-type (wt) or Bax-null (k/o) cells were incubated for 24 h with IL-3 and 1.25 mM hydroxyurea (HU) as indicated. They were then stained with the caspase substrate PhiPhiLux and caspase-inactive and caspase-active populations were analysed by FACScan as described in Materials and methods. (b) The plating eciency of cultures from Bax-null mice or normal littermate controls in IL-3 plus various concentrations of HU was measured as described in Figure 1 . This was then expressed as a fraction of the plating eciency in IL-3 alone. Values shown are the mean+standard error of triplicate determinations performed with independent cultures
